Several new blood‐based biomarkers—including phospho‐tau 217, neurofilament light chain, glial fibrillary acidic protein, and several other emerging markers of neuroinflammation—are well positioned to contribute to this goal and assist in the identification of older adults at imminent risk of AD‐related cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.